Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Clinical trial NCT05756907 · TERMINATED

Trial details

NCT number: NCT05756907
Sponsor: Sonnet BioTherapeutics
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Platinum-resistant Ovarian Cancer

Start date: 2023-09-15
Primary completion: 2025-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.